TumorGrafts are becoming increasingly popular in published scientific research and have received a fair amount of press coverage. Below are a sampling of patient-initiated posts about TumorGrafts and Champions, a selections of media coverage related to TumorGrafts, and a listing of recent publications in leading scientific journals on TumorGraft technology.
Linking to the below content and sites does not necessarily reflect an endorsement from Champions Oncology.
Patients In Their Own Words
- A mother's book written for her child about her cancer and tumorgrafting.
- Top Five Reasons Why I Love Champions Oncology (post link)
- Tumour grafting - my investment in innovation (blog link)
- A mother's perspective on Champions and TumorGrafting for her daughter (post dated August 19, 2011)
- WUSA 9 News Report on Champions TumorGraftsTM and personalized oncology.
- Talk About Health Q&A with Dr David Sidransky on personalizing cancer treatment through TumorGrafts.
A Molecularly Annotated Platform of Patient-Derived Xenografts (''Xenopatients'') Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Bertotti A et al. Cancer Discovery 2011;1:508-523.
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
Villarroel M et al. Mol Cancer Ther 2010;10:3-8
A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Hidalgo M et al. Mol Cancer Ther. 2011 Aug;10(8):1311-6.
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
DeRose Y et al. Nat Med. 2011 Oct 23;17(11):1514-20
Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft
Morelli M et al. J Clin Oncol. 2012 Feb 1;30(4):e45-8
Additional Scientific Resources
Assessment of Celecoxib Pharmacodynamics in Pancreatic Cancer
Jimeno A et al. Mol Cancer Ther 2006, 5 (12): 3240-7
An In Vivo Platform for Translational Drug Developmentin Pancreatic Cancer
Rubio Viqueira B et al. Clin Cancer Res 2006, 12(15)
Development of Two Novel Benzoylphenylurea Sulfur Analogues and Evidence that the Microtubuleassociated Protein Tau is Predictive of Their Activity in Pancreatic Cancer
Jimeno A et al. Mol Cancer Ther 2007, 6(5):1509–16
Dual Mitogen-Activated Protein Kinase and Epidermal Growth Factor Receptor Inhibition in Biliary and Pancreatic Cancer
Jimeno A et al. Mol Cancer Ther 2007, 6(3):1079–88
Optimizing the Development of Targeted Agents in Pancreatic Cancer: Tumor Fine-Needle Aspiration Biopsy as a Platform for Novel Prospective Ex Vivo Drug Sensitivity Assays
Rubio Viqueira B et al. Mol Cancer Ther 2007, 6(2):515–23
Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer
Jimeno A et al. Cancer Res 2008, 68(8): 2841–9
Evaluation of the Novel Mitotic Modulator ON 01910.Na in Pancreatic Cancer and Preclinical Development of an Ex Vivo Predictive Assay
Jimeno A et al. Oncogene 2008, 1–9
A Direct Pancreatic Cancer Xenograft Model as a Platform for Cancer Stem Cell Therapeutic Development
Jimeno A et al. Mol Cancer Ther 2009, 8(2):OF1–5
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
Jimeno A et al. J Clin Oncol. 2009 Mar 1;27(7):1130-6
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok T et al. N Engl J Med 2009; 361:947-957
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch T et al. N Engl J Med 2004; 350:2129-2139
Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Winer E et al. J Clin Oncol 27:812-826, 2008
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen Z et al. Nature. 2012 Mar 18;483(7391):613-7